Compare iShares Semiconductor ETF (SOXX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Semiconductor ETF trades at $552.6, while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). Which is the better fit depends on your goals.
| SOXX | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $655.01 | $529.59 |
52-Week Low | $236.93 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX, the iShares Semiconductor ETF, trades at $524.14, up 0.45% on the day but down 20% from its June 2026 all-time high, reflecting a sector-wide correction. Technical indicators are bearish, with the ETF facing resistance near $533. Recent news highlights a sharp pullback in semiconductor stocks amid concerns over AI-driven valuations and cyclical pressures, though long-term demand drivers remain intact.
The outlook for SOXX is cautious near-term due to technical weakness and sentiment headwinds, but the ETF's concentrated exposure to leading chipmakers offers growth potential if AI and memory demand persist. Key risks include sector volatility, valuation concerns, and macroeconomic shifts impacting tech spending.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
